- Home
- NRIX vs QURE Comparison
NRIX vs QURE Comparison
Compare NRIX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | QURE |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NRIX | QURE |
|---|---|---|
| Price | $19.17 | $25.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $29.08 | ★ $58.55 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 01-27-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $83,687,000.00 | $15,751,000.00 |
| Revenue This Year | $59.40 | N/A |
| Revenue Next Year | N/A | $153.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 48.32 | N/A |
| 52 Week Low | $8.18 | $7.76 |
| 52 Week High | $22.50 | $71.50 |
Technical Indicators
Market Signals| Indicator | NRIX | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 53.26 |
| Support Level | $16.98 | $22.11 |
| Resistance Level | $19.92 | $24.43 |
| Average True Range (ATR) | 0.90 | 1.41 |
| MACD | -0.22 | 0.59 |
| Stochastic Oscillator | 72.82 | 54.80 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.